Hugo Geerts on Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
COMMENT Another disappointing but not unexpected result. The hope is that we can learn a lot about the clinical trial design with regard to “confounding” parameters. A major underestimated problem is the effect size of the pharmacodynamic interactions between β-a